References
- Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18(2):326-82
- Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11(7):557-70
- Grimprel E, Njamkepo E, Begue P, Guiso N. Rapid diagnosis of pertussis in young infants: comparison of culture, PCR, and infant’s and mother’s serology. Clin Diagn Lab Immunol 1997;4(6):723-6
- Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 Suppl):S58-61
- Hegerle N, Guiso N. Epidemiology of whooping cough & typing of Bordetella pertussis. Future Microbiol 2013;8:1391-403
- Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin S, Orenstein WA, Offit PA, editors. Vaccines. 4th edition. Saunders; Philadelphia, USA: 2008. p. 471-528
- Njamkepo E, Cantinelli T, Guigon G, Guiso N. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes infect 2008;10(14-15):1582-6
- Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of bordetella pertussis and their relationship with vaccination. mBio 2014;5(2):e01074
- Hegerle N, Paris AS, Brun D, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012;18(9):E340-6
- Bordet J, Sleeswijk JG. Sérodiagnostic et variabilité des microbes suivant le milieu de culture. Ann Inst Pasteur (Paris) 1910;24(6):476-94
- Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012;5(5):485-500
- Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014;209(7):978-81
- Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014;111(2):787-92
- Carlsson RM, Trollfors B. Control of pertussis – lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009;27(42):5709-18
- Barkoff AM, Mertsola J, Guillot S, et al. Appearance of Bordetella pertussis strains not expressing vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012;19(10):1703-4
- Lam C, Octavia S, Ricafort L, et al. Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia. Emerg Infect Dis 2014;20(4):626-33
- Miyaji Y, Otsuka N, Toyoizumi-Ajisaka H, et al. Genetic analysis of. Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One 2013;8(10):e77165
- Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol 2014;21(2):119-25
- Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013;368(6):583-4
- Quinlan T, Musser KA, Currenti SA, et al. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis. 2004Mol Cell Probes 2014;28(4):138-40
- Cherry JD, Tan T, Wirsing von Konig CH, et al. Clinical definitions of pertussis: summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis 2012;54(12):1756-64